ACA
MIST icon

Aptus Capital Advisors’s Milestone Pharmaceuticals MIST Stock Holding History

Aptus Capital Advisors’s Portfolio MIST Stock Details MIST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$333K Buy
280,250
+17,050
+6% +$29.9K ﹤0.01% 841
2025
Q4 		$532K Buy
263,200
+53,000
+25% +$114K ﹤0.01% 714
2025
Q3 		$420K Buy
+210,200
New +$370K ﹤0.01% 744

Other funds holding MIST

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Aptus Capital Advisors's MIST Position: Q1 2026 in Review

Aptus Capital Advisors increased its Milestone Pharmaceuticals (MIST) stake by 6.5% in Q1 2026, buying an estimated $29.9K and bringing the position to 280,250 shares worth $333K. The position accounts for ﹤0.01% of the portfolio, ranked #841.

Aptus Capital Advisors first reported a position in MIST in Q3 2025 and has held it in 3 quarters since. The position peaked at $532K in Q4 2025. 86 funds tracked by Wall St. Rank hold MIST as of Q1 2026.

  • Aptus Capital Advisors held 280,250 shares of Milestone Pharmaceuticals worth $333K as of Q1 2026.
  • Aptus Capital Advisors bought 17,050 Milestone Pharmaceuticals shares in Q1 2026, an estimated $29.9K.
  • Milestone Pharmaceuticals made up ﹤0.01% of Aptus Capital Advisors's portfolio in Q1 2026, its #841 holding.
  • Aptus Capital Advisors first reported a position in Milestone Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Aptus Capital Advisors's Milestone Pharmaceuticals position peaked at $532K in Q4 2025.
  • 86 funds tracked by Wall St. Rank held Milestone Pharmaceuticals as of Q1 2026.

Based on Aptus Capital Advisors's 13F filing for Q1 2026, filed 11 May 2026.